牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-22-000759 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-22-015189 Act: 33 Size: 795 KB 网页链接
$灿菲特生物制药(CANF)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-22-014672 Act: 34 Size: 7 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-014654 Act: 34 Size: 80 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-011985 Act: 34 Size: 27 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-011706 Act: 34 Size: 22 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-010997 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-22-022536 Act: 34 Size: 64 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-22-006670 Act: 34 Size: 53 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001393825-22-000097 Act: 34 Size: 56 KB 网页链接